Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib Combined With BEAM as a Preconditioning Regimen for ASCT in Relapsed and Refractory DLBCL
NCT07774299Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Sponsor
- Ruijin Hospital
- Drugs
- pirtobrutinib
- Conditions
- diffuse large B-cell lymphoma (DLBCL)
01
Overview
Phase 2, open-label, single-arm trial of pirtobrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Primary endpoint: Progression-free survival up to 2 years. Planned start Aug 2026; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
pirtobrutinib + BEAM
pirtobrutinib combined with BEAM as conditioning therapy followed by ASCT
03
Who it enrols
Adults aged 18-70 with relapsed/refractory DLBCL who achieved CR or PR after second-line or later treatment, with ECOG 0-2, adequate organ function, and no prior ASCT.
04
Endpoints
Primary
Progression-free survival
Secondary
Overall survival
Complete remission rate
The time of hematopoietic reconstruction
Transplantation-related adverse reactions
Beyond the preview
Go deeper on NCT07774299.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07774299.